EGFR and non-small cell lung carcinoma: Randomized phase III trials showed progression free survival (PFS) and response rate (RR) benefit of EGFR TKIs compared to platinum-doublets chemotherapy as first line treatment of EGFR mutated NSCLC [4–7], with subsequent post-hoc or preplanned subgroup analyses revealing higher benefit in cases harbouring classical exon 19 deletion [5–10].